Cellares and TScan Therapeutics agreed to evaluate automated clinical manufacturing of TSC-101, TScan’s lead TCR-T cell therapy candidate for AML and MDS patients undergoing allogeneic hematopoietic cell transplantation. The deal aims to test whether Cellares’ automated Cell Shuttle platform and Cell Q quality control system can reduce variability and labor while improving scalability. TSC-101 is engineered from healthy donor T cells into a patient-specific product to address residual disease and reduce relapse risk post-transplant. TScan expects to start a pivotal trial in the second quarter of 2026 and is using the manufacturing evaluation for commercial readiness. Cellares will automate manufacturing and release testing processes under closed, fully automated workflows designed to minimize process variability and capacity constraints. The collaboration is framed as a strategy to make cell therapy more consistent across runs and geographies. The agreement reflects the field’s push to industrialize cell therapy production ahead of larger registrational studies and broader patient access.